On October 16, Julio Triana, Global President of Bayer Consumer Health and a member of the Bayer Group Management Board, emphasized the company’s long-standing commitment to the Chinese market. “Bayer has been in China for over 140 years, and we look forward to deepening our presence here for another 140 years,” he stated during an interview with a reporter from China News Service in Shanghai.
This announcement coincided with the official launch of the Bayer Consumer Health China Center of Innovation and Partnership (CCIP) at the Shanghai Biomedical Frontier Innovation Center. As one of Bayer’s global strategic innovation bases, the CCIP is expected to invest around 20 million euros. Its goal is to foster innovation and cooperation in the pharmaceutical and health sectors through science-based approaches, focusing on consumer needs to expedite research and development. This facility aims to help the company explore self-care solutions that cater to Chinese consumers.
In the interview, Triana further elaborated, “The Chinese market is full of potential, and there is a significant demand from Chinese consumers for high-quality self-care solutions. Bayer’s business in China is experiencing rapid growth. The establishment of CCIP is a significant step in enhancing our investment in China, allowing us to embody the concept of ‘In China, for China, benefiting the world.'”
Arturo Sanchez, President of Bayer Consumer Health for the Asia-Pacific and Latin American regions, added, “China has quickly become Bayer Consumer Health’s second-largest market globally in just seven years. We hope to leverage China’s successful experiences and replicate them in other Asia-Pacific markets, providing strong support for the company’s strategic implementation in the region and beyond.”
The CCIP is committed to promoting open innovation and collaboration. It aims to build an integrated innovation network encompassing industry, academia, and research institutions, thereby accelerating innovation and the translation of research findings into practical applications in the health sector.
During the CCIP opening ceremony, Zhang Qing, Deputy Director of the Shanghai Drug Administration, highlighted Shanghai’s strong emphasis on the biomedical industry. He expressed hope that foreign enterprises would leverage their strengths in tandem with Shanghai’s technological and policy advantages to seize the opportunities presented by China’s modernization.
